Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Sponsor: Wake Forest University Health Sciences
Summary
The purpose of this prospective study is to evaluate the degree of post-inflammatory pigmentation alteration on legs of study subjects treated with two different psoriasis treatments. Betamethasone dipropionate 0.05% cream is a high potency steroid that is commonly used to alleviate the inflammation of psoriasis. Tapinarof is another medication approved for psoriasis; tapinarof activates aryl hydrocarbon receptors to downregulate inflammatory cytokines (such as interleukin \[IL\]-17) which play a large role in psoriasis. Study subjects will be randomized to receive one of these medications and will be followed to monitor for PIPA. Photographs will be taken to help evaluate visual changes. The Taylor Hyperpigmentation scale will be used to grade the area and severity of hyperpigmentation and hypopigmentation; severity of erythema, burning, peeling, and dryness will also be recorded. This will allow us to understand the effects of two standard-of-care psoriasis medications to better treat patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-07-15
Completion Date
2026-12
Last Updated
2025-12-17
Healthy Volunteers
No
Conditions
Interventions
Betamethasone dipropionate 0.05%
0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
Tapinarof
1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
Locations (1)
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, United States